Solaris Vaccines Joins BioMaP and RRPV to Protect Public Health


Solaris Vaccines is proud to announce its selection as a member of the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP), an assembly of industry leaders across the biopharmaceutical manufacturing spectrum collaborating to bolster the nation's preparedness efforts to support the Biomedical Advanced Research and Development Authority (BARDA).

Along with BioMaP, Solaris Vaccines has joined the Rapid Response Partnership Vehicle (RRPV), a cornerstone in fortifying national health security, dedicated to proactively developing medical countermeasures both preceding and during pandemics or public health crises. With a primary focus on expediting product and technology advancement, regulatory approval processes, commercialization endeavors, and long-term sustainability efforts, the RRPV stands ready to confront challenges posed by pandemic influenza, emerging infectious diseases, and other biological threats head-on.

"Our SolaVAX vaccine platform is uniquely suited for preparing for pandemic threats," stated Dr. Michael Artinger, Solaris CEO. "We look forward to working with our partners in the US Government to protect our Country from both current and future global outbreaks of deadly infectious diseases." 

About Solaris Vaccines, Inc.

Solaris Vaccines, Inc. was formed 2021 to address many of the challenges of creating vaccines in response to emerging threats to global human health. Current methods of developing and manufacturing vaccines are slow, not fully protective, technically complex, use toxic chemicals, and often have onerous storage requirements. The Solaris SolaVAX™ method uses riboflavin (vitamin B2) and UV light to rapidly and effectively inactivate pathogens, resulting in a new approach for creating vaccines against pathogens such as viruses, bacteria and parasites. Go to to learn more.